These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22327368)

  • 21. Progress of artificial pancreas devices towards clinical use: the first outpatient studies.
    Russell SJ
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):106-11. PubMed ID: 25692927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.
    Del Favero S; Place J; Kropff J; Messori M; Keith-Hynes P; Visentin R; Monaro M; Galasso S; Boscari F; Toffanin C; Di Palma F; Lanzola G; Scarpellini S; Farret A; Kovatchev B; Avogaro A; Bruttomesso D; Magni L; DeVries JH; Cobelli C; Renard E;
    Diabetes Obes Metab; 2015 May; 17(5):468-76. PubMed ID: 25600304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances toward the implantable artificial pancreas for treatment of diabetes.
    Jaremko J; Rorstad O
    Diabetes Care; 1998 Mar; 21(3):444-50. PubMed ID: 9540030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas.
    Ang KH; Tamborlane WV; Weinzimer SA
    Expert Opin Drug Deliv; 2015; 12(10):1579-82. PubMed ID: 26389567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.
    Spaic T; Driscoll M; Raghinaru D; Buckingham BA; Wilson DM; Clinton P; Chase HP; Maahs DM; Forlenza GP; Jost E; Hramiak I; Paul T; Bequette BW; Cameron F; Beck RW; Kollman C; Lum JW; Ly TT;
    Diabetes Care; 2017 Mar; 40(3):359-366. PubMed ID: 28100606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological aspects of closed loop insulin delivery for type 1 diabetes.
    Uduku C; Oliver N
    Curr Opin Pharmacol; 2017 Oct; 36():29-33. PubMed ID: 28802779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps.
    Pickup JC
    Diabetes Technol Ther; 2011 Jul; 13(7):695-8. PubMed ID: 21668344
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
    Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
    Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose Control During Physical Activity and Exercise Using Closed Loop Technology in Adults and Adolescents with Type 1 Diabetes.
    Zaharieva DP; Messer LH; Paldus B; O'Neal DN; Maahs DM; Riddell MC
    Can J Diabetes; 2020 Dec; 44(8):740-749. PubMed ID: 33011134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin Therapy and Diabetic Pregnancy.
    Napoli A
    Am J Ther; 2020; 27(1):e91-e105. PubMed ID: 31688066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery.
    Kovatchev B; Cheng P; Anderson SM; Pinsker JE; Boscari F; Buckingham BA; Doyle FJ; Hood KK; Brown SA; Breton MD; Chernavvsky D; Bevier WC; Bradley PK; Bruttomesso D; Del Favero S; Calore R; Cobelli C; Avogaro A; Ly TT; Shanmugham S; Dassau E; Kollman C; Lum JW; Beck RW
    Diabetes Technol Ther; 2017 Jan; 19(1):18-24. PubMed ID: 27982707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
    Ly TT; Weinzimer SA; Maahs DM; Sherr JL; Roy A; Grosman B; Cantwell M; Kurtz N; Carria L; Messer L; von Eyben R; Buckingham BA
    Pediatr Diabetes; 2017 Aug; 18(5):348-355. PubMed ID: 27191182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of glucose-responsive 'smart' insulin systems.
    Rege NK; Phillips NFB; Weiss MA
    Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):267-278. PubMed ID: 28509691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.
    Weinzimer SA; Steil GM; Swan KL; Dziura J; Kurtz N; Tamborlane WV
    Diabetes Care; 2008 May; 31(5):934-9. PubMed ID: 18252903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Who needs an artificial pancreas? (？).
    Winikoff J; Drexler A
    J Diabetes; 2013 Sep; 5(3):254-7. PubMed ID: 23601378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study.
    van Bon AC; Hermanides J; Koops R; Hoekstra JB; DeVries JH
    J Diabetes Sci Technol; 2010 Jul; 4(4):923-8. PubMed ID: 20663458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The artificial pancreas.
    Boughton CK; Hovorka R
    Curr Opin Organ Transplant; 2020 Aug; 25(4):336-342. PubMed ID: 32618719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The artificial pancreas: how close are we to closing the loop?
    Clarke WL; Kovatchev B
    Pediatr Endocrinol Rev; 2007 Jun; 4(4):314-6. PubMed ID: 17643078
    [No Abstract]   [Full Text] [Related]  

  • 39. Automated Insulin Delivery-The Light at the End of the Tunnel.
    Turksoy K; Frantz N; Quinn L; Dumin M; Kilkus J; Hibner B; Cinar A; Littlejohn E
    J Pediatr; 2017 Jul; 186():17-28.e9. PubMed ID: 28396030
    [No Abstract]   [Full Text] [Related]  

  • 40. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.